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Available online 29 February 2008Glutaric aciduria type 1 (GA1) is caused by the deﬁciency of glutaryl-CoA dehydrogenase (GCDH). Affected
patients are prone to the development of encephalopathic crises during an early time window with
destruction of striatal neurons and a subsequent irreversible movement disorder. 3-Hydroxyglutaric acid
(3OHGA) accumulates in tissues and body ﬂuids of GA1 patients and has been shown to mediate toxic effects
on neuronal as well as endothelial cells. Injection of (3H)-labeled into 6 week-old Gcdh−/− mice, a model of
GA1, revealed a low recovery in kidney, liver, or brain tissue that did not differ from control mice. Signiﬁcant
amounts of 3OHGA were found to be excreted via the intestinal tract. Exposure of Gcdh−/− mice to a high
protein diet led to an encephalopathic crisis, vacuolization in the brain, and death after 4–5 days. Under these
conditions, high amounts of injected 3H-3OHGA were found in kidneys of Gcdh−/− mice, whereas the
radioactivity recovered in brain and blood was reduced. The data demonstrate that under conditions
mimicking encephalopathic crises the blood–brain barrier appears to remain intact.
© 2008 Elsevier B.V. All rights reserved.Keywords:
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Metabolic crisis1. Introduction
Glutaric aciduria type 1 (GA1, MIM 231670) is caused by defects of
the mitochondrial matrix protein glutaryl-CoA dehydrogenase (GCDH,
EC 1.3.99.7), an enzyme involved in the degradation of the amino acids
lysine, hydroxylysine and tryptophan.Mutations in the GCDHgene lead
to the accumulation of glutaric acid (GA), 3-hydroxyglutaric acid
(3OHGA), and in some patients also glutaconic acid in body ﬂuids and
tissues. GA1 patients are prone to the development of encephalopathic
crises triggered by catabolic stress induced by fever, infections,
vomiting and/or diarrhea. During these catabolic crises, concentrations
of the metabolites show a further increase. The development of an
encephalopathic crisis is accompanied by destruction of striatal
neurons with a subsequent irreversible disabling movement disorder.
Children affected by GA1 are at risk for such a crisis during a time
window from 3 to 36 months of age. After completion of the third year
of life an encephalopathic crisis occurs only sporadically [1,2]. Current: +49 40 42803 8504.
Mühlhausen).
l rights reserved.therapeutic approaches focus on the restriction of lysine intake, sta-
bilization of energy supply, replenishing the diminished carnitine pool,
and implementation of intensiﬁed therapy during illness with acute
catabolic states [3,4]. Newborn screening techniques have been
implemented to identify GA1 patients presymptomatically [5]. Despite
early treatment and intensiﬁed management, a proportion of GA1
patients still suffer encephalopathic crises [6,7].
Several underlying mechanisms of GA1 have been discussed. It has
been assumed that 3OHGA is the GA1-speciﬁc metabolite crucial for
the disease-speciﬁc symptoms because GA also accumulates in other
organic acidurias [8]. Thus, several effects of 3OHGA have been
described: excitotoxic effects in vitro, depletion of energy-releasing
phosphates, and impairment of endothelial barrier properties in vitro
and in vivo [8–12].
A Gcdh-deﬁcient mouse displays a biochemical and histopatholo-
gical phenotype resembling ﬁndings in GA1 patients but develops no
encephalopathic crises [13]. However, exposure of young Gcdh−/−mice
to a high protein and/or high lysine diet induces an increase of GA and
3OHGA in body ﬂuids and tissues accompanied by acute striatal injury
and neuronal loss, appearing as strikingmovement disorder, paralysis,
seizures and death occurring within 2–8 days [12]. Furthermore,
Table 1
Tissue distribution of (3H)-3OHGA in Gcdh−/− and control mice under basal conditions
Tissue Recovery of radioactivity (%)
42 d 100 d
Wildtype Gcdh−/− Wildtype Gcdh−/−
Kidney 2.5 (2.2–2.8) 2.95 (1.3–3.7) 2.55 (2.5–2.6) 4.5 (2.4–6.6)
Liver 4.35 (3.7–5) 1.45 (1.3–2)a 3.95 (3–4.9) 3.95 (3.5–4.4)
Brain 6.05 (4.8–7.3) 2.95 (1.2–4.1)a 4.75 (2.9–6.6) 4.25 (4.1–4.4)
Blood 51.5 (34–69) 53 (40–64) 49 (29–69) 44 (34–54)
Stomach/bowel/
faeces
7.55 (5.6–9.5) 14.5 (13.8–29)a 36.8 (11.6–62) 16.1 (10.2–22)
Radioactivity was determined in the indicated tissues (% of total recovered radioactivity
exclusive of radioactivity excreted into urine) in wildtype and Gcdh−/− mice. Values
represent median and range of 2-4 experiments per group. Signiﬁcance was tested by
Mann–Whitney-U tests.
a Different but not signiﬁcant (p=0.06).
Table 2
GA and 3OHGA concentrations in 42 d old Gcdh−/− mice on normal diet and HPD
GA 3OHGA
Gcdh−/− ND Gcdh−/− HPD Gcdh−/− ND Gcdh−/− HPD
Plasma (µmol/l) 255±180 338±204 7.2±2.1 ⁎10.5±1.8
Urine (mmol/mol
creatinine)
33,926±6056 ⁎50,934±9927 898±126 ⁎1414±168
Concentrations of endogenous GA and 3OHGA were determined at day 4 of dietary
treatment. ND: normal diet; HPD: high protein diet. Levels are given as means±SD of
determinations in 4–5 independent animals per group. Signiﬁcance (HPD vs. ND) was
tested by unpaired two-tailed t-test. ⁎pb0.05.
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crisis has been described [12]. Disturbances in the integrity of
intracerebral endothelial barriers have also been considered in GA1
patients [14]. Previous in vitro and in vivo studies have shown that in
the presence of 3OHGA functional properties of endothelial cells are
impaired and the integrity of vasculature and endothelial barriers are
disrupted [11].
In the present report we used (3H)-labeled 3OHGA to monitor the
tissue distribution and excretion of 3OHGA in wildtype and Gcdh−/−
mice in vivo. We also evaluated the effect of a diet-induced
encephalopathic crisis on the tissue distribution and excretion of
3OHGA, and the integrity of the blood–brain barrier. We show that in
6 week-old Gcdh−/−mice circulating (3H)-3OHGA enters the brain only
to a very limited extent under both basal conditions and during a diet-Fig. 1. Survival of Gcdh−/− mice during diet-induced encephalopathic crises. Surviving percen
n=15). HPD treatment was started at 38 d of age, designated as day 1 of HPD exposure. 55%induced encephalopathic crisis. In contrast the kidney levels of (3H)-
3OHGA are signiﬁcantly elevated during a diet-induced crisis. We also
report a signiﬁcant role for the gut in the excretion of 3OHGA.
2. Materials and methods
2.1. Mice
Gcdh−/− mice and wild type littermate controls were generated from heterozygotes
[13]. The genetic background in all mice groups used in this study was C57BL6/SJ129
hybrid. Genotypes were conﬁrmed by PCR and measurement of glutarylcarnitine
concentration in dried blood spots. Mice were housed in the animal facility of the
University Medical Center with a 12-hour light-dark cycle and allowed water and food
ad libitum. Animal care and experiments were carried out in accordance with
institutional guidelines as approved by local authorities.
2.2. (3H)-3OHGA distribution in vivo
(3H)-3OHGAwas synthesized as described previously [15]. Mice at an age of 42 and
100 days fed for 4 days with standard or high protein (HPD) diet were injected
intravenously with (3H)-3OHGA (107 cpm in 50 µl phosphate buffered saline pH 7.4).
During incubation time, urine and faeces were collected. After 2 or 6 h mice were
anesthetized, intracardiac blood and intravesicular urine were sampled, and animals
were instantly perfused with 0.9% NaCl solution. Organs (brain, liver and kidneys) were
removed and solubilized in Tissue Solubilizer according to the manufacturer's
instructions (NCS-II, Amersham Buchler, Germany). Additionally, stomach and bowel
were removed and dissected. Faeces were collected and all three samples processed
separately as described above. To prevent effects of tissue chromogens on scintillation
counting, samples were decolourized by addition of small aliquots of 30% hydrogen
peroxide (H2O2), and counted in Rotiszint (Roth, Karlsruhe, Germany).
2.3. Injection and detection of ﬂuorescence-labeled dextrans
Forty-two day-old wildtype and Gcdh−/− mice fed on normal diet or HPD were
injectedwith 3 kDa biotin-,10 kDa biotin-,10 kDa Alexa Fluor 594- or 70 kDa ﬂuorescein-
labeled dextran (Catalog-Nos. D7135, D1956, D22913, andD1822, respectively;Molecular
Probes, Eugene, OR, USA; 5 µg/g body weight). After 1 h of incubation, animals were
anaesthetized, perfusedwith 4% paraformaldehyde inphosphate buffered saline (pH7.4),
and organs were parafﬁn-embedded and cut in 3 µm sections. Fluorescence-labeled
dextrans were visualized using a Leica DMIRE 2 confocal ﬂuorescence microscope
applying the respective excitationwavelengths. Biotin-labeled sampleswere treatedwith
streptABComplex/HRP duet (Dako, Copenhagen, Denmark) according to the manufac-
turer's instructions and visualized using a Zeiss Axiovert S100 microscope.
2.4. Histology and immunohistochemistry
For histologic examination, sections of organs of 42 d old wildtype and Gcdh−/−
mice fed on normal diet or HPD were deparafﬁnized, hydrated and either stained with
HE or treated with appropriate antigen retrieval regimens. Immunohistochemical
stainings for glial ﬁbrillary acidic protein (GFAP) were carried out using standard
protocols [16]. For quantiﬁcation of vacuoles, 5 representative regions of cortex,
hippocampus and striatum were assessed. Quantiﬁcation was performed by counting
numbers of vacuoles per visual ﬁeld (283×214 µm).tage of Gcdh−/−mice fed with HPD (black boxes, n=11) and normal diet (white triangles,
of Gcdh−/− mice on HPD had died at day 4 of HPD exposure, 91% at day 5.
387B. Keyser et al. / Biochimica et Biophysica Acta 1782 (2008) 385–3902.5. Determination of GA, 3OHGA and glutarylcarnitine
GA and 3OHGA in plasma and urine were quantiﬁed by GC/MS using stable isotope
standards as described previously [17]. Glutarylcarnitine concentrations in mouse bile
were determined by electrospray MS/MS spectrometry [18].Fig. 2. Increased vacuolization in Gcdh−/− brain tissue during encephalopathic crises. HE-stai
(B, D, F). Cortex (A, B), hippocampus (C, D) and striatum (E, F) show vacuolization under basal
G: Quantiﬁcation of number of vacuoles per visual ﬁeld (283×214 µm) in HE-stained brain sli
HPD. For each group (Gcdh−/− on normal diet vs. Gcdh−/− on HPD), 2 animals were examined; 5
determined using unpaired, two-tailed t-tests and accepted at pb0.05. ⁎pb0.05; ⁎⁎pb0.0012.6. Data analysis
Signiﬁcance was tested as indicated in the ﬁgure legends and accepted at p≤0.05.
Calculations were performed using Microsoft Excel 2003 and SPSS 12.0 software (SPSS
Inc., Chicago, IL, USA).ned brains of 42 d old Gcdh−/− mice fed for 4 days with a normal diet (A, C, E), or a HPD
conditions, further increasing under conditions of a diet-induced encephalopathic crisis.
ces shows a signiﬁcant increase in the number of vacuoles in brains of Gcdh−/−mice on a
visual ﬁelds were counted per animal and region, respectively. Level of signiﬁcancewas
. Bars: 25 µm.
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3.1. Tissuedistributionof (3H)-3OHGA inGcdh−/−miceunder basal conditions
The tissue distribution of (3H)-3OHGA was determined 2 and 6 h
after intravenous injection in 100 d old mice under basal conditions.
The majority of radioactivity (90–95%) was found in urine. Due to
lower variability in radioactivity recovered from tissues and blood, all
further experiments were performed using an incubation period of 6 h
after injection of (3H)-3OHGA.
To examine tissue distribution of (3H)-3OHGAunder basal conditions,
(3H)-3OHGA was intravenously injected into 42 and 100 d old wildtype
and Gcdh−/− mice. Six hours after injection, animals were sacriﬁced and
radioactivity was determined in blood, urine and tissues (kidney, liver,
brain, stomach, bowel, faeces) by scintillation counting. When the
radioactivity found in urine was subtracted, approximately 2–6% of (3H)-
3OHGA were recovered in kidney, liver or brain tissue (Table 1). The
increased level of endogenous 3OHGA in plasma of 42 d old Gcdh−/−mice
(Table 2) competing with (3H)-3OHGA for putative transporter binding
sites might explain the reduced (p=0.06) content of radioactivity in liver
and brain tissue (Table 1). About half of the radioactivity was still in the
circulation. Surprisingly, a signiﬁcant amount of (3H)-3OHGA was
detected in stomach, bowel and faeces. Although this percentage was
variable, Gcdh−/− mice at an age of 42 d appear to excrete more (3H)-
3OHGA into the gut and via faeces than control mice.With the exception
of stomach, bowel and faeces, the tissue and blood distribution of (3H)-
3OHGA in Gcdh−/−mice did not differ signiﬁcantly from control mice, nor
between 42 and 100 d oldmice (Table 1). The percentage of (3H)-3OHGA
excreted via stomach, bowel and faeces of wildtype mice appears to
increase with age, whereas no changes were observed between young
and older Gcdh−/− mice.
3.2. Tissue distribution of (3H)-3OHGA during an encephalopathic crisis
To examine characteristics of Gcdh−/− mice under conditions of an
encephalopathic crisis, we studied animals exposed to a high protein
diet (HPD) [12]. In an attempt tomodel the timewindowof vulnerability
seen in human GA1 patients [2], and the age-dependence of diet-
induced encephalopathic crises in Gcdh−/− mice [12], these investiga-Fig. 3. Tissue distribution of intravenously injected (3H)-3OHGA. Percentage of recovered
excreted via urine. Bars represent median±range, data are derived from 4 independent exper
tissue of HPD-treated Gcdh−/− mice compared to Gcdh−/− mice on normal diet, accompani
reduced in Gcdh−/−mice on HPD compared to controls. On a normal diet, Gcdh−/−mice had inc
with wildtype mice. This was reversed in HPD-treated mice. Levels of signiﬁcance were testionswere performedwith 42 d oldmice. Under our conditions, ≥90% of
38doldGcdh−/−micediedafter 4–5days ofHPD treatment (Fig.1). Onset
of symptoms (reduced body temperature, reduced and dystonic move-
ments) was observed 12–24 h prior to death of affected mice. HPD
exposure did not affect either age-matched wildtype control or hetero-
zygous Gcdh+/− mice (data not shown). In comparison to Gcdh−/− mice
fed with a normal diet, Gcdh−/− mice on HPD showed a signiﬁcant
increase of metabolites in plasma (3OHGA: 10.5±1.8 vs. 7.2±2.1 µmol/l)
and urine (GA: 50,934±9,927 vs. 33,926±6,056 mmol/mol creatinine;
3OHGA: 1,414±168 vs. 898±126mmol/mol creatinine) (Table 2). Deter-
mination of glutarylcarnitine revealed signiﬁcantly increased levels
in bile of Gcdh−/−mice compared to heterozygote and wildtype animals
(Supplementary Fig. 1).
Examination of brains after transcardiac perfusion revealed extra-
vasation of blood into the subarachnoid space aswell as intraventricular
blood surrounding the choroid plexus in 42 d old Gcdh−/− mice
maintained on HPD (Supplementary Fig. 2D–H). Histologic examination
showed no evidence of erythrocyte degradation or hematoma forma-
tion, indicating that the blood was the result of an acute subarachnoid
haemorrhage, and not a chronic process (Supplementary Fig. 2G–H).
There was no evidence of intracerebral bleeding in Gcdh−/− mice on a
normal diet, or in wildtype controls on either diet (Supplementary
Fig. 2A–C). Exposure to the HPD also signiﬁcantly increased the number
of vacuoles in the cortex, striatum and hippocampus of 42 d old Gcdh−/−
mice (6-, 3- and 2-fold, respectively; Fig. 2). No vacuoles were observed
in brains of wildtype mice fed with normal diet or HPD (not shown).
GFAP-speciﬁc stainingof brain sliceswas similar inwildtype andGcdh−/−
mice, on both diets, indicating that the HPD did not result in gliosis
(Supplementary Fig. 3). To determine whether organs other than the
brain were affected by the HPD, we examined the kidney and bowel of
wildtype and Gcdh−/− mice on a normal diet or after 4 days of the HPD.
During 4 days of the HPDwater intake as well as the volume of urine in
Gcdh−/−micewere similar and slightly increased, respectively, compared
to Gcdh−/− mice on normal diet. HE-stained sections of the kidney
revealed neither glomerular, nor tubular abnormalities in any of the
mice. Similarly, the appearance of the intestinal brush border was
similar in all of the mice (Supplementary Fig. 4).
To investigate whether endothelial barrier functions are altered
under conditions of an encephalopathic crisis, we compared the tissueradioactivity 6 h after intravenous injection of (3H)-3OHGA exclusive of radioactivity
iments per group. There is a signiﬁcant accumulation of (3H)-3OHGA in kidney and liver
ed by a reduction of radioactivity in blood. In contrast, intracerebral (3H)-3OHGA was
reased excretion of (3H)-3OHGAvia faeces (s/b/f: stomach, bowel, faeces) in comparison
ted using Mann–Whitney-U tests. ⁎pb0.05. #p=0.06.
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normal diet and after four days of the HPD. In wildtype animals the
HPD had no effect on the tissue distribution of (3H)-3OHGA (Fig. 3). In
contrast, a striking effect of the HPD was observed in the kidneys of
Gcdh−/− mice, which demonstrated a 16- to 32-fold increase of
perfusion-resistant radioactivity. An increased accumulation of (3H)-
3OHGAwas also seen in the liver (5-fold). Signiﬁcantly reduced levels
of (3H)-3OHGA were observed in the blood (∼4-fold) and brains (5-
fold) of HPD-fed Gcdh−/− mice compared to HPD-treated wildtype
animals. The capability to excrete (3H)-3OHGA into the stomach,
bowel and faeces found in Gcdh−/− mice on the normal diet was not
observed in HPD-fed Gcdh−/− mice.
We also evaluated endothelial barrier function via intravenous
injection of ﬂuorescent-labeled dextrans (3, 10 and 70 kDa) into 42 d
old wildtype and Gcdh−/− mice on either normal diet or the HPD. One
hour after injection none of the examined animals showed any
extravasation of the labeled dextrans in the brain or in the kidney
(data not shown). These results, and the data on brain levels of (3H)-
3OHGA, indicate that under conditions mimicking an encephalopathic
crisis the blood–brain barrier appears to remain intact, preventing the
inﬂux of (3H)-3OHGA into the brain from the systemic circulation.
4. Discussion
After intravenous injection of (3H)-3OHGA in control mice small
amounts of radioactivity were recovered from the tissues studied,
whereas the majority was excreted into the urine. The tissue
distribution pattern was similar in 42 and 100 d old control mice. In
young Gcdh−/− mice, however, the distribution of the (3H)-labeled
metabolite was changed in comparison to wildtype animals. The
amount of (3H)-3OHGAwas reduced in brain tissue suggesting that the
steep gradient of 3OHGAbetween brain tissue and plasma [18] reduces
the inﬂux of (3H)-3OHGA into the brain. Alternatively, competitive
binding of endogenously produced organic acids (Table 2) with
injected (3H)-3OHGAmay explain the data in Gcdh−/−mice. Moreover,
alterations in the transport capacity of endothelial barriers for (3H)-
3OHGA are likely. We have recently identiﬁed the ﬁrst transporter for
3OHGA, the sodium-dependent dicarboxylate transporter 3 (NaC3;
Slc13a3), which is localized in basolateral membranes of proximal
tubule cells as well as in astroglial cells [15,19]. The expression of NaC3
is upregulated in kidneys of Gcdh−/−mice. The transporters at the apical
membranes of endothelial cells responsible for the inﬂux of 3OHGA
into the brain and how they are regulated are presently unknown.
Interestingly, a signiﬁcant proportion of injected (3H)-3OHGA was
found in the stomach, bowel and faeces of wildtype mice, and an even
higher amount in Gcdh−/− mice, indicating the existence of additional
pathways to secrete 3OHGA into the gut. The level of glutarylcarnitine
is signiﬁcantly elevated in the bile of Gcdh−/− mice (Supplementary
Fig. 1), suggesting that biliary excretion is one of the mechanisms
responsible for the accumulation of labeled 3OHGA in the gut. The
clinical signiﬁcance of this faecal route of excretion, and its correlation
with the phenomenon of high and low urine excretors among GA1
patients is unknown. These subgroups are deﬁned by the concentra-
tions of GA and 3OHGA they excrete into the urine, which correlates
with residual GCDH activity and with distinct alleles, e.g. p.R227P, but
not with clinical phenotype [17,20,21].
A high protein diet induced an encephalopathic crisis in Gcdh−/−
mice that was lethal to 42 day-old animals within 5 days (Fig. 1). This
was associated with accumulation of GA and 3OHGA in serum and
urine (Table 2), a signiﬁcant increase in the numbers of vacuoles in
speciﬁc regions of the brain (Fig. 2), and subarachnoid haemorrhages
(Supplementary Fig. 2). In contrast to ﬁndings in 28 d old Gcdh−/−mice
exposed to a high lysine diet for 3 days [12], no evidence of blood–brain
barrier breakdown was observed under conditions used in this study.
The inﬂux of (3H)-3OHGA into the brain was actually reduced, rather
than increased, after 4 days exposure to a high protein diet (Fig. 3).These data are also surprising because it was found that 2 mM 3OHGA
impairs both the VEGF-induced endothelial tube formation in vitro as
well as chick chorioallantoic membrane (CAM) integrity in vivo [11].
Differences between the concentrations of 3OHGA and VEGF used in
tube formation and CAM assays, and the actual serum 3OHGA level in
Gcdh−/− mice might explain the discrepancies. On the other hand, a
strong accumulation of injected (3H)-3OHGA was found in the kidney
of Gcdh−/−mice after 4 days exposure to a high protein diet (Fig. 3). The
renal clearance of 3OHGA is substantially greater than the GFR
indicating that the renal clearance occurs mainly via tubular secretion
[22]. In proximal tubule cells the transport of dicarboxylates such asGA
and 3OHGA is mediated by organic anion transporters (OAT) and NaC3
[15,23]. Recently, OAT1 and OAT4 were identiﬁed as high afﬁnity
transporters for GA and 3OHGA [24], which were found to be localized
at the basolateral and apical membrane, respectively, of human
proximal tubule cells. Therefore, the data suggest that during
metabolic crises in Gcdh−/− mice, injected (3H)-3OHGA is translocated
from the blood across the basolateral membrane of renal proximal
tubule cells via OAT1 and NaC3. However, the secretion of (3H)-3OHGA
at the apical side into the urine appears to be impaired, resulting in an
accumulation of the substrate in kidneys. OAT4 has been detected only
in human but so far not in mice [23]. The 3OHGA transporter at the
apical membrane of proximal tubular cells in mice, most likely an
OAT4-like transporter, and the regulated expression of transporters
during metabolic crisis remain to be investigated.
We have shown that the inﬂux of (3H)-3OHGA from the circulation
into the brain tissue of wildtype mice is low, conﬁrming data with
deuterium-labeled 3OHGA [18]. Additionally, our present study
provides evidence that in Gcdh−/− mice both under basal conditions
and during encephalopathic crises the permeability of the blood–brain
barrier for 3OHGA and ﬂuorescence-labeled dextranswas not affected,
suggesting that organic acids produced by brain cells are responsible
for neuropathological alterations rather than metabolites formed in
peripheral organs. Finally, we report that signiﬁcant amounts of
3OHGA can be excreted via the intestinal tract, which might present a
novel target for therapeutic interventions in GA1 patients.
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